Continue reading here:
Ozempic and other weight loss drugs may be linked to conditions that could lead to blindness, study says - Quartz
How Ageism Impacts Adults with Low Vision National Council on Aging
Read more here:
How Ageism Impacts Adults with Low Vision - National Council on Aging
Foundation Fighting Blindness Celebrates 20 Years of VisionWalk PR Newswire
Read the original here:
Foundation Fighting Blindness Celebrates 20 Years of VisionWalk - PR Newswire
Treatment for Horses May Lead to Therapy for Type of Blindness Morning Ag Clips -
Go here to read the rest:
Treatment for Horses May Lead to Therapy for Type of Blindness - Morning Ag Clips -
Some Ozempic users are losing their vision - but scientists dont know why The Independent
Read more from the original source:
Some Ozempic users are losing their vision - but scientists dont know why - The Independent
Woman Victim of 'Lash Blindness'Shock at How She Looks Without Them Newsweek
Read more from the original source:
Woman Victim of 'Lash Blindness'Shock at How She Looks Without Them - Newsweek
Medical warning: Ozempic and Mounjaro may be linked to vision loss India Today
View original post here:
Medical warning: Ozempic and Mounjaro may be linked to vision loss - India Today
Those with visual impairments or blindness tackling the trails at Pico Mountain WCAX
View post:
Those with visual impairments or blindness tackling the trails at Pico Mountain - WCAX
Ozempic Blindness: Weight Loss Drugs Linked to This Condition, Experts Warn Tech Times
Read the original:
Ozempic Blindness: Weight Loss Drugs Linked to This Condition, Experts Warn - Tech Times
New research links Ozempic to vision loss and risk of blindness MSN
Read more here:
New research links Ozempic to vision loss and risk of blindness - MSN
Excerpt from:
Ozempic Blindness Lawsuit Mounts: Shocking Side Effect Of Weight Loss Drug Is 'Eye Stroke,' What You Need To Know - IBTimes UK
The Politics Of Erasure: Gaza, Genocide, And The Wests Wilful Blindness OpEd Eurasia Review
More:
The Politics Of Erasure: Gaza, Genocide, And The Wests Wilful Blindness OpEd - Eurasia Review
-Interim clinical study updates for the first three Subjects treated with BB-301 in the Phase 1b/2a Clinical Treatment Study to be presented as a late-breaking oral presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference on March 19, 2025- -Interim clinical study updates for the first three Subjects treated with BB-301 in the Phase 1b/2a Clinical Treatment Study to be presented as a late-breaking oral presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference on March 19, 2025-
See the article here:
Benitec Biopharma Announces Acceptance of Late- Breaking Oral Abstract for the BB-301 Phase 1b/2a Clinical Study at the Muscular Dystrophy Association...
MADRID and CAMBRIDGE, Mass., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the final results of the Phase IIa REIMAGINE study, which evaluated the safety and efficacy of vafidemstat on aggression in adult patients with borderline personality disorder (BPD), attention-deficit/hyperactivity disorder (ADHD), and autistic spectrum disorder (ASD), were published online in Psychiatry and Clinical Neurosciences. A summary of the final data from this study had been previously released at the 2020 European Psychiatry Association (EPA) annual meeting.
Read the rest here:
ORYZON Announces Journal Publication of Final Phase IIa REIMAGINE Results with Vafidemstat in Psychiatry and Clinical Neurosciences
COPENHAGEN, Denmark, February 14, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has received confirmation from the Nasdaq Stock Market LLC (“Nasdaq”) that it has re-established compliance with Nasdaq’s minimum stockholders’ equity requirement. Nasdaq has withdrawn its determination to delist Evaxion, and the company will remain listed as fully compliant with Nasdaq’s rules.
Visit link:
Nasdaq confirms Evaxion is fully compliant, withdraws delisting determination
ISELIN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced financial results for the first quarter of fiscal year 2025 and provided a corporate update.
-Fifth Subject in BB-301 Phase 1b/2a Clinical Treatment Study safely treated in February 2025-
Read the rest here:
Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update
SOLANA BEACH, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced nonclinical results on ART12.11, its proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP). The findings were presented by Professor Saoirse O’Sullivan, Vice President of Translational Science at Artelo Biosciences, at the International Medical Cannabis Conference (IMCCB-25), held February 13-14, 2025, at the University of Bern, Switzerland.
NEW YORK, Feb. 14, 2025 (GLOBE NEWSWIRE) -- February 14, 2025 – IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, yesterday presented Phase 1 data on its allogeneic gamma-delta T cell therapy, INB-100, at the 2025 Transplantation & Cellular Therapy (TCT) Meetings in Hawaii. The data, previously announced, reinforce INB-100’s potential to significantly reduce post-transplant relapse in high-risk acute myeloid leukemia (AML) patients, positioning this gamma-delta T cell therapy as a promising approach in hematologic oncology.
See the article here:
IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML